SG11202102851XA - SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF - Google Patents
SIRPa BINDING PROTEINS AND METHODS OF USE THEREOFInfo
- Publication number
- SG11202102851XA SG11202102851XA SG11202102851XA SG11202102851XA SG11202102851XA SG 11202102851X A SG11202102851X A SG 11202102851XA SG 11202102851X A SG11202102851X A SG 11202102851XA SG 11202102851X A SG11202102851X A SG 11202102851XA SG 11202102851X A SG11202102851X A SG 11202102851XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- binding proteins
- sirpa binding
- sirpa
- proteins
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 101150036449 SIRPA gene Proteins 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737782P | 2018-09-27 | 2018-09-27 | |
US201962853997P | 2019-05-29 | 2019-05-29 | |
PCT/US2019/052604 WO2020068752A1 (en) | 2018-09-27 | 2019-09-24 | SIRPα BINDING PROTEINS AND METHODS OF USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102851XA true SG11202102851XA (en) | 2021-04-29 |
Family
ID=69953545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102851XA SG11202102851XA (en) | 2018-09-27 | 2019-09-24 | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
Country Status (16)
Country | Link |
---|---|
US (1) | US20240034789A1 (es) |
EP (1) | EP3856787A4 (es) |
JP (2) | JP7266670B2 (es) |
KR (1) | KR20210086619A (es) |
CN (1) | CN113166245A (es) |
AU (1) | AU2019349651B2 (es) |
BR (1) | BR112021005585A2 (es) |
CA (1) | CA3113798A1 (es) |
CL (1) | CL2021000738A1 (es) |
CO (1) | CO2021003724A2 (es) |
IL (1) | IL281783A (es) |
MX (1) | MX2021003393A (es) |
PE (1) | PE20211491A1 (es) |
SG (1) | SG11202102851XA (es) |
TW (1) | TW202028237A (es) |
WO (1) | WO2020068752A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201912879YA (en) | 2016-12-09 | 2020-02-27 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
EP3802602A1 (en) | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン, インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
TW202214303A (zh) | 2020-05-19 | 2022-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之結合分子 |
BR112022023371A2 (pt) * | 2020-05-22 | 2022-12-20 | Chongqing Prec Biotech Co Ltd | Proteína de fusão para reversão do microambiente tumoral, vetor de expressão, célula imune, receptor de antígeno quimérico resistente à imunossupressão tumoral, sequência de ácido nucleico, método para preparar uma célula imune, composição farmacêutica, e, uso da composição farmacêutica |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
KR20240027677A (ko) | 2021-06-04 | 2024-03-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-sirp-알파 항체 |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US20240165229A1 (en) | 2021-06-29 | 2024-05-23 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
WO2023010076A1 (en) * | 2021-07-30 | 2023-02-02 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
AU2022322029A1 (en) | 2021-08-05 | 2024-02-15 | Immunos Therapeutics Ag | Combination medicaments comprising hla fusion proteins |
AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012059562A1 (en) * | 2010-11-03 | 2012-05-10 | Argen-X-Bv | C-met antibody combinations |
US9574002B2 (en) * | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
WO2015138600A2 (en) * | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
GB201503387D0 (en) * | 2015-02-27 | 2015-04-15 | ALERE TECHNOLOGIES GmbH | Anti-carbapenem antibodies and uses thereof |
JP2018510151A (ja) * | 2015-03-06 | 2018-04-12 | ソレント・セラピューティクス・インコーポレイテッド | Tim3に結合する抗体医薬 |
HRP20211980T1 (hr) * | 2015-04-07 | 2022-04-01 | Alector Llc | Protutijela protiv sortilina i postupci njihove upotrebe |
SG11201808465UA (en) * | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
EP3493845A4 (en) * | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
US20200140565A1 (en) * | 2016-10-20 | 2020-05-07 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
SG10201912879YA (en) * | 2016-12-09 | 2020-02-27 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
-
2019
- 2019-09-24 WO PCT/US2019/052604 patent/WO2020068752A1/en active Application Filing
- 2019-09-24 MX MX2021003393A patent/MX2021003393A/es unknown
- 2019-09-24 JP JP2021517284A patent/JP7266670B2/ja active Active
- 2019-09-24 EP EP19867552.2A patent/EP3856787A4/en active Pending
- 2019-09-24 TW TW108134495A patent/TW202028237A/zh unknown
- 2019-09-24 SG SG11202102851XA patent/SG11202102851XA/en unknown
- 2019-09-24 BR BR112021005585-1A patent/BR112021005585A2/pt unknown
- 2019-09-24 AU AU2019349651A patent/AU2019349651B2/en active Active
- 2019-09-24 CN CN201980075667.9A patent/CN113166245A/zh active Pending
- 2019-09-24 PE PE2021000361A patent/PE20211491A1/es unknown
- 2019-09-24 KR KR1020217011852A patent/KR20210086619A/ko unknown
- 2019-09-24 CA CA3113798A patent/CA3113798A1/en active Pending
-
2021
- 2021-03-24 CO CONC2021/0003724A patent/CO2021003724A2/es unknown
- 2021-03-24 IL IL281783A patent/IL281783A/en unknown
- 2021-03-24 CL CL2021000738A patent/CL2021000738A1/es unknown
-
2023
- 2023-02-01 US US18/162,879 patent/US20240034789A1/en active Pending
- 2023-02-27 JP JP2023028936A patent/JP2023078167A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019349651A1 (en) | 2021-04-29 |
JP7266670B2 (ja) | 2023-04-28 |
PE20211491A1 (es) | 2021-08-11 |
EP3856787A1 (en) | 2021-08-04 |
TW202028237A (zh) | 2020-08-01 |
JP2023078167A (ja) | 2023-06-06 |
KR20210086619A (ko) | 2021-07-08 |
BR112021005585A2 (pt) | 2021-06-29 |
AU2019349651B2 (en) | 2023-12-07 |
WO2020068752A1 (en) | 2020-04-02 |
WO2020068752A8 (en) | 2021-02-04 |
CN113166245A (zh) | 2021-07-23 |
EP3856787A4 (en) | 2022-06-29 |
US20240034789A1 (en) | 2024-02-01 |
IL281783A (en) | 2021-05-31 |
JP2022502051A (ja) | 2022-01-11 |
CO2021003724A2 (es) | 2021-07-30 |
CA3113798A1 (en) | 2020-04-02 |
MX2021003393A (es) | 2021-05-13 |
CL2021000738A1 (es) | 2021-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202102851XA (en) | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF | |
IL261432A (en) | Induced binding proteins and methods of use | |
IL275782A (en) | Multispecific antigen binding proteins and methods of use thereof | |
IL261666A (en) | Related proteins and methods of using them | |
EP3635013A4 (en) | NECTIN-4 BINDING PROTEINS AND PROCESSES FOR USE | |
IL288071A (en) | Epcam binding proteins and methods of use | |
IL264211A (en) | Multispecific antigen binding proteins and methods of using them | |
IL281683A (en) | DLL3 binding proteins and methods of use | |
IL274151A (en) | Trispecific binding proteins and methods of use | |
HK1251158A1 (zh) | Pd-1結合蛋白及其使用方法 | |
IL246921B (en) | Binding proteins and their uses | |
IL265489B (en) | Recombinant binding proteins and their uses | |
IL279201A (en) | Multispecific binding proteins and methods of using them | |
IL269074A (en) | Proteins that bind anti-TIGIT antigens and methods of using them | |
IL284157A (en) | Anti-pd-1 binding proteins and methods of using them | |
IL284156A (en) | Binding proteins against ctla-4 and methods of using them | |
IL284364A (en) | Anti-pd-l1 binding proteins and methods of using them | |
IL283231A (en) | dpep-1 binding factors and methods of use | |
HUP1700012A2 (en) | Novel proteins and use thereof |